NeuroScientific Biopharmaceuticals reports on preclinical program

Latest News

NeuroScientific Biopharmaceuticals (ASX:NSB) has reported positive outcomes from its preclinical safety and toxicology program involving its lead drug candidate EmtinB.

The company said the preclinical program was undertaken to support the commencement of first-in-human clinical trials.

It said EmtinB demonstrated an "impressive" safety profile in multiple animal species with no major adverse effects or toxicology findings.

Managing director and CEO Matt Liddelow said, “We are excited to report the outstanding safety outcomes for EmtinB and the successful completion of the Preclinical Safety and Toxicology Program to support initiation of Phase I clinical studies for our neurology indications.

"This safety data provides clear validation that we have met all requirements of achieving the significant milestone of advancing our novel lead drug candidate EmtinB into the clinical development phase and we have been working closely with our clinical development partner Linear Clinical Research to execute on our first-in-human clinical trial in 1H 2022.”